CJC Open最新文献

{"title":"Female Representation in the Antiplatelet Medication Literature Informing the 2023 Canadian Antiplatelet Guidelines","authors":"Nicole L. Tegg MN, RN,&nbsp;Kainat Meherali,&nbsp;Jenna Semmens RN,&nbsp;Colleen M. Norris PhD, RN, FAHA, FCAHS","doi":"10.1016/j.cjco.2026.03.004","DOIUrl":"10.1016/j.cjco.2026.03.004","url":null,"abstract":"<div><div>Antiplatelet medications remain essential in managing atherosclerotic cardiovascular disease. We assessed the adequacy of female representation in the antiplatelet medication literature, which informed the 2023 Canadian Antiplatelet Guidelines. Literature cited in the 2023 Canadian Antiplatelet Guidelines was systematically reviewed. Randomized controlled trials were included. Observational studies, systematic reviews, guidelines, consensus documents, studies missing demographic data, and research protocols were excluded. Extracted data included study titles, author, year, design, sample size, mean participant age, and proportion of female participants. Of 138 identified unique citations, 109 studies met the inclusion criteria. From the included evidence informing the 7 antiplatelet PICO (population, intervention, comparison, outcome) topics, the total sample size was 570,217 participants, with a mean age of 65.4 years. The mean percentage of female participants included across trials was 28.5%, and 21% of the included studies had a participation-to-prevalence ratio of 0.8-1.2 for female participants. Female patients were not adequately represented in nearly two-thirds of the evidence informing antiplatelet medication trials. Thus, the 2023 Canadian Antiplatelet Guidelines PICO topics are informed largely by evidence with inadequate female representation. A need remains for greater attention to adequately representing female patients in clinical trials for antiplatelet medications, which in turn inform clinical guidelines.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 7","pages":"Pages 908-913"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The PARTHENON Registry: Acknowledging Value While Addressing the Gaps","authors":"Fatih Aydin MD, PhD","doi":"10.1016/j.cjco.2026.03.013","DOIUrl":"10.1016/j.cjco.2026.03.013","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 7","pages":"Page 793"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appraising the Quality of Patient Decision Aids for Brain and Heart Health: An Environmental Scan with a Health Equity Lens","authors":"Krystina B. Lewis RN, PhD,&nbsp;Sandhya Goge RN, MN,&nbsp;Alda Kiss RN, MScN,&nbsp;Meg Carley,&nbsp;Ann Marie Julien,&nbsp;Gloria Higdon,&nbsp;Jess G. Fiedorowicz MD, PhD,&nbsp;Ian D. Graham PhD, FCAHS, FNYAM, FRSC,&nbsp;Amélie M. Achim PhD,&nbsp;Rob Beanlands MD, FRCPC,&nbsp;Semhal Gessese RN, MScN,&nbsp;Sharon Straus HBSc, MSc, MD, FRCP(C),&nbsp;Jodi Edwards PhD,&nbsp;Mathieu Bujold PhD,&nbsp;Sheldon Tobe MD, MScCH (HPTE), FRCPC, FACP, FASH,&nbsp;Dawn Stacey RN, PhD, FRSC, FCAHS, FAAN, FCAN,&nbsp;uOttawa Brain–Heart Interconnectome (BHI) program","doi":"10.1016/j.cjco.2026.03.012","DOIUrl":"10.1016/j.cjco.2026.03.012","url":null,"abstract":"<div><h3>Background</h3><div>New brain–heart clinical practice guidelines recommend provision of patient decision aids (PtDAs) to support people with or at risk of brain and heart conditions. We aimed to identify and appraise the quality of PtDAs addressing brain–heart conditions and their consideration of health equity.</div></div><div><h3>Methods</h3><div>We conducted an online environmental scan to identify publicly available PtDAs. Two reviewers independently searched, extracted data, and appraised their quality using International Patient Decision Aid Standards (IPDAS) criteria, the Patient Education Materials Assessment Tool (PEMAT), and the PROGRESS-Plus framework for health equity.</div></div><div><h3>Results</h3><div>Of 2549 resources identified, 51 PtDAs were eligible. Nine addressed a combined brain–heart decision, 36 addressed primarily cardiovascular conditions with brain implications, and 6 addressed primarily brain conditions with heart implications. Few focused on brain–heart conditions concomitantly. None addressed dementia, and only one addressed depression as a primary condition with cardiovascular risk addressed as a secondary consideration. The mean IPDAS essential criteria score was 5.8 of 7 (SD 1.5, range 1-7). For PEMAT-P (for printable materials), 91% PtDAs achieved an adequate understandability rating (≥ 70%), and 56% achieved an adequate actionability rating (≥ 70%). The most frequently reported PROGRESS-Plus healthy equity items were age (80%), gender/sex (45%), and socioeconomic status (39%).</div></div><div><h3>Conclusions</h3><div>Brain–heart guidelines recommend PtDA use, but our environmental scan highlighted the need for more of these important interventions. Few PtDAs focused on brain and heart conditions concomitantly, none addressed dementia, and only one addressed depression, which frequently coexist with cardiac conditions. PtDAs also lacked actionable guidance within an equity-informed framework to support quality decisions and decision-making processes for all.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 7","pages":"Pages 897-907"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Key Insights on the Impact of Sacubitril–Valsartan in Canada, Despite Limitations of Registry Data","authors":"Michael A. McDonald MD,&nbsp;Melanie Kok MSc, PhD,&nbsp;Anique Ducharme MD, MSc,&nbsp;Justin Ezekowitz MBBCh, MSc,&nbsp;Jonathan Howlett MD,&nbsp;Carlos Rojas-Fernandez PharmD,&nbsp;Jacob A. Udell MD, MPH","doi":"10.1016/j.cjco.2026.04.018","DOIUrl":"10.1016/j.cjco.2026.04.018","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 7","pages":"Pages 794-795"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valve-Sparing Resection of Aortic Papillary Fibroelastoma in an Elderly Patient with Recurrent Stroke","authors":"Adam Kowalówka MD, PhD,&nbsp;Mikołaj Jodłowski MD,&nbsp;Anna Bednarek MD, PhD,&nbsp;Radosław Gocoł MD, PhD","doi":"10.1016/j.cjco.2026.03.003","DOIUrl":"10.1016/j.cjco.2026.03.003","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 7","pages":"Pages 828-830"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148546786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction to “Vaccination in Patients With Cardiovascular Disease: A Case-based Approach and Contemporary Review [Canadian Journal of Cardiology Open. Volume 7, Issue 10 (2025), 1375-1388]”","authors":"Phelopater Sedrak MD ,&nbsp;Vera Dounaevskaia MD ,&nbsp;G.B. John Mancini MD ,&nbsp;Shelley Zieroth MD ,&nbsp;Robert S. McKelvie MD, PhD ,&nbsp;Wynne Chiu MSN, RN, CCN(C) ,&nbsp;Grace L. Chua MD ,&nbsp;David Bewick MD ,&nbsp;Anique Ducharme MD, MSc ,&nbsp;Samer Mansour MD ,&nbsp;Serge Lepage MD ,&nbsp;Glen J. Pearson PharmD, FCSHP, FCCS ,&nbsp;Robert C. Welsh MD ,&nbsp;Jacob A. Udell MD, MPH ,&nbsp;Kim A. Connelly MBBS, PhD","doi":"10.1016/j.cjco.2026.01.005","DOIUrl":"10.1016/j.cjco.2026.01.005","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 6","pages":"Page 689"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Path Less Traveled: Embracing the Arts in Scientific Communications","authors":"Laura Banks PhD, MA","doi":"10.1016/j.cjco.2026.01.009","DOIUrl":"10.1016/j.cjco.2026.01.009","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 6","pages":"Pages 687-688"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Cardiovascular Disease Risk Assessment in Nonclinical Settings: Framingham-Simplified Model Predictive Performance in a Canadian Cohort","authors":"Jacquecin Garçon MPH ,&nbsp;Mathilde Lavigne-Robichaud PhD ,&nbsp;Alain Milot MD ,&nbsp;Denis Talbot PhD ,&nbsp;Mahée Gilbert-Ouimet PhD ,&nbsp;Chantal Brisson PhD ,&nbsp;Clermont E. Dionne PhD ,&nbsp;Xavier Trudel PhD","doi":"10.1016/j.cjco.2026.01.014","DOIUrl":"10.1016/j.cjco.2026.01.014","url":null,"abstract":"<div><h3>Background</h3><div>The Framingham risk model is recommended for estimating 10-year cardiovascular disease (CVD) risk in Canada. Its simplified version (Framingham-SP) replaces lipids with body mass index, eliminating the need for laboratory testing. The predictive performance of the Framingham-SP in Canada is unknown. This external validation study assessed the discrimination and calibration of the Framingham-SP model in a prospective cohort from Quebec, Canada.</div></div><div><h3>Methods</h3><div>The study sample included 3692 women and 3671 men free of CVD at baseline (1999-2001; follow-up until 2011). Incident CVD events were identified using medico-administrative databases. Multiple imputation was used to handle missing data. Discrimination was assessed using C-statistics. Calibration was evaluated using calibration-in-the-large, absolute difference, and discordance.</div></div><div><h3>Results</h3><div>Over the 10-year follow-up, 211 CVD events occurred among women and 453 occurred among men. For women, the predicted 10-year CVD risk was 4.07% (95% confidence interval [CI]: 3.94-4.20), and the observed risk was 5.72% (95% CI: 5.01-6.51). The C-statistic was 0.72 (95% CI: 0.68-0.76). For men, the predicted risk was 11.73% (95% CI: 11.44-12.02), and the observed risk was 12.34% (95% CI: 11.32-13.44). The C-statistic was 0.72 (95% CI: 0.69-0.74). Overall, calibration was lower among women, particularly those in intermediate and high predicted risk categories.</div></div><div><h3>Conclusions</h3><div>The Framingham-SP model demonstrated acceptable predictive performance in this Canadian cohort. Its simplified format may help support preliminary CVD risk assessment and lifestyle counselling, including in nonclinical settings, while remaining complementary to guideline-based clinical evaluation. Recalibration may improve performance among high-risk women.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 6","pages":"Pages 690-699"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus-Based Marking Schemes to Assess Competence Using Free-Text Echocardiogram Summary Statements","authors":"Vinay Jayachandiran MD ,&nbsp;Aws Almufleh MBBS, MPH ,&nbsp;Annabel Chen-Tournoux MD ,&nbsp;Nicolas Thibodeau-Jarry MD, MMSc ,&nbsp;Parvathy Nair MD ,&nbsp;Sarah Blissett MD, MHPE","doi":"10.1016/j.cjco.2026.02.003","DOIUrl":"10.1016/j.cjco.2026.02.003","url":null,"abstract":"<div><h3>Background</h3><div>Summary statements of transthoracic echocardiography (TTE) reports can be used to assess trainees’ competence in TTE interpretation. However, the inherent variability in wording and composition of summary statements creates challenges for developing marking schemes. This study aims to develop consensus-based marking schemes for TTE summary statements.</div></div><div><h3>Methods</h3><div>A modified Delphi approach with 2 rounds of surveys and a consensus-finalizing meeting was conducted to establish items that should be included in the summary statement and items critical to fulfill competence. Via consensus (defined as &gt; 80% agreement), experts determined what items always should be included, and what items should be included in specific indications or cardiac diagnoses.</div></div><div><h3>Results</h3><div>The first and second round surveys were completed by 27 experts. Eleven experts participated in the consensus-finalizing meeting. This process established that 79 items should be included in the summary statement. Five general items (left ventricular [LV] size, LV systolic function, right ventricular size and right ventricular function, and a statement about valves) should be included in all summary statements, and the remaining 74 items should be included in the presence of abnormalities, specific indications, or relevant diagnoses. Sixteen items were deemed critical for competence. Only LV systolic function was deemed critical to fulfill competence in all summary statements, with the remaining 15 items critical in specific indications.</div></div><div><h3>Conclusions</h3><div>These findings inform consensus-based marking schemes for TTE summary statements. When integrated into competence assessments, these findings will inform the training of TTE interpretation for cardiology residents.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 6","pages":"Pages 736-747"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Practice Patterns and Barriers to Intravascular Imaging–Guided Percutaneous Interventions: Insights from a Canadian Nationwide Survey","authors":"Mehdi Madanchi MD ,&nbsp;Natalia Pinilla-Echeverri MD, PhD ,&nbsp;Kevin R. Bainey MD, MSc ,&nbsp;Andrea Lavoie MD ,&nbsp;Samer Mansour MD ,&nbsp;Tej Sheth MD ,&nbsp;Matthew Sibbald MD, PhD","doi":"10.1016/j.cjco.2026.02.019","DOIUrl":"10.1016/j.cjco.2026.02.019","url":null,"abstract":"<div><h3>Background</h3><div>Despite robust evidence supporting use of intravascular imaging (IVI) to guide complex percutaneous coronary intervention (PCI), its adoption across Canada remains poorly defined.</div></div><div><h3>Methods</h3><div>A standardized cross-sectional electronic survey was distributed to catheterization laboratory directors across Canada.</div></div><div><h3>Results</h3><div>Sites were evenly distributed between academic (9; 43%) and nonacademic (12; 57%) institutions, with a mean annual PCI volume of 1706 ± 722 procedures. IVI integration into the catheterization laboratory was reported in 38 of 56 laboratories (68%), with a median of 6 PCI operators (interquartile range, 5-9) per site. Operator comfort levels were generally good, with the majority of catheterization laboratory directors describing their operators as being somewhat experienced (6; 29%) or very experienced (9; 43%). Most directors (90%) perceived IVI as having a positive impact on outcomes. Overall, results showed a trend toward an increase in IVI-guided PCI between 2022 and 2024 (15.6% vs 19.1%, <em>P</em> = 0.7). The most-cited barriers to broader IVI use were increased procedure time (76%), cost of equipment or devices (67%), and reimbursement challenges (48%), with no differences between Ontario and non-Ontario sites (40% vs 33%, <em>P</em> = 1.0). Over half (52%) of centres were planning to complete IVI upgrades within the next 2 years.</div></div><div><h3>Conclusions</h3><div>Although IVI is widely available in Canadian catheterization laboratories, it remains underused, due to barriers related to procedure time, workflow, and cost. A coordinated effort among key stakeholders is needed to reduce current barriers and promote broader guideline-concordant use and IVI adoption.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"8 6","pages":"Pages 729-735"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}